Media stories about Lantheus Holdings (NASDAQ:LNTH) have been trending somewhat negative on Saturday, according to AlphaOne. The research group, a service of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Lantheus Holdings earned a media sentiment score of -0.01 on AlphaOne’s scale. AlphaOne also assigned press coverage about the medical equipment provider an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Alpha One’s rankings:
- Lantheus Holdings, Inc. (LNTH) Expected to Announce Earnings of $0.24 Per Share (americanbankingnews.com)
- After-Hours Stock Movers 06/14: (APPS) (ROX) (LAKE) Higher; (PACB) (LNTH) (OAKS) Lower (more…) (streetinsider.com)
- The Zacks Analyst Blog Highlights: Lantheus Holdings, Nutrisystem, Telecom Argentina, Chemours and British American Tobacco (finance.yahoo.com)
- Short Interest in Lantheus Holdings, Inc. (LNTH) Grows By 159.4% (americanbankingnews.com)
- Lantheus Holdings, Inc. (LNTH) CEO Sells $153,900.00 in Stock (americanbankingnews.com)
Lantheus Holdings (NASDAQ LNTH) opened at 15.10 on Friday. The company’s 50-day moving average price is $15.76 and its 200-day moving average price is $11.80. The stock has a market cap of $562.67 million, a PE ratio of 25.34 and a beta of 0.93. Lantheus Holdings has a 12-month low of $2.51 and a 12-month high of $17.45.
Lantheus Holdings (NASDAQ:LNTH) last issued its quarterly earnings data on Tuesday, May 2nd. The medical equipment provider reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.09. The company had revenue of $81.36 million during the quarter, compared to analyst estimates of $77.75 million. Lantheus Holdings had a negative return on equity of 24.06% and a net margin of 6.71%. On average, equities analysts expect that Lantheus Holdings will post $0.93 EPS for the current fiscal year.
LNTH has been the subject of a number of recent research reports. Zacks Investment Research upgraded Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $17.00 target price for the company in a report on Thursday, May 4th. Jefferies Group LLC lifted their target price on Lantheus Holdings from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, May 3rd.
In related news, CEO Mary Anne Heino sold 10,000 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $15.39, for a total value of $153,900.00. Following the completion of the transaction, the chief executive officer now directly owns 602,468 shares in the company, valued at $9,271,982.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Michael P. Duffy sold 20,000 shares of the stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $15.42, for a total value of $308,400.00. Following the completion of the transaction, the insider now owns 188,234 shares of the company’s stock, valued at $2,902,568.28. The disclosure for this sale can be found here. Insiders sold 3,050,000 shares of company stock valued at $40,967,300 over the last quarter. 2.30% of the stock is currently owned by company insiders.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.